Research progress of omics biomarkers for nonalcoholic fatty liver disease

VernacularTitle:非酒精性脂肪性肝病组学生物标志物的研究进展
Author: Lin WANG ¹ ; Xueen LIU ; Hui ZHUANG
Author Information

1. 北京大学医学部病原生物学系和感染病中心　100191
Keywords: Liver fibrosis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Non-alcoholic fatty liver; Omics biomarkers
From: Chinese Journal of Hepatology 2021;29(6):604-608
CountryChina
Language:Chinese
Abstract: Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide and it includes simple fatty liver disease (NAFL), nonalcoholic steatohepatitis (NASH), liver cirrhosis, and hepatocellular carcinoma-related NASH. The degree of hepatic necrotizing inflammation and fibrosis is closely related to the long-term prognosis of NAFLD patients. Therefore, early monitoring of disease progression and intervention are of great significance. Liver biopsy, as an invasive test, has always been the gold standard for the diagnosis of NAFLD; however, it is not easy to carry out widely in clinical practice. With the development of omics-related research technologies, the potential application value of omics biomarkers such as genomics, transcriptomics, proteomics, glycomics, metabolomics, and so on in the diagnosis of NAFLD has gradually emerged. This review mainly summarizes the research progress of omics biomarkers for NAFLD.